Calliditas Therapeutics AB (publ), a commercial-stage specialty pharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was founded in 2004 and is headquartered in Stockholm, Sweden.
Frequently asked questions
What sector does Calliditas Therapeutics AB (publ) (CLTEF) operate in?
Calliditas Therapeutics AB (publ) belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Calliditas Therapeutics AB (publ) (CLTEF) current stock price?
As of the latest data, Calliditas Therapeutics AB (publ) stock price is $0.10, with a previous close of $0.10.
What is Calliditas Therapeutics AB (publ) (CLTEF) current market capitalization?
Calliditas Therapeutics AB (publ) market cap is approximately 504.72 million.
What is Calliditas Therapeutics AB (publ) (CLTEF) Earnings Per Share (EPS)?
The trailing EPS is -$1.07.
Does Calliditas Therapeutics AB (publ) (CLTEF) pay dividends?
No. Calliditas Therapeutics AB (publ) does not pay a dividend.
What is Calliditas Therapeutics AB (publ) (CLTEF) beta (volatility) score?
Calliditas Therapeutics AB (publ) has a beta of 1.283, suggesting it is more volatile than the market.
